Using an average price of $54.14 per ADR, the deal implies a value of $175 for each Alexion share. Find the latest Alexion Pharmaceuticals, Inc. (ALXN) stock quote, history, news and other vital information to help you with your stock trading and investing. Alexion Pharmaceuticals has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. The deal values Alexion at $175 per share, a 45% premium to the Boston biotech’s closing price on Friday. Earnings for Alexion Pharmaceuticals are expected to grow by 5.30% in the coming year, from $11.14 to $11.73 per share. Real time Alexion Pharmaceuticals (ALXN) stock price quote, stock graph, news & analysis. Alexion Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. With Alexion Pharmaceuticals stock trading at $152.75 per share, the total value of Alexion Pharmaceuticals stock (market capitalization) is $33.43B. Alexion Pharmaceuticals stock was originally listed at a price of $3.13 in Dec 31, 1997 . Biogen beats Alexion Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Founded in the early 1990s, Alexion today is best known for high-priced treatments for uncommon illnesses. ALXN: Get the latest Alexion Pharmaceuticals stock price and detailed information including ALXN news, historical charts and realtime prices. Summary. The cash and stock deal, the largest in AstraZeneca’s AZN, -0.86% history, values Alexion ALXN, +0.09% at $175 per share and has been agreed upon by the boards of directors of both companies. The offer values Alexion at $175 a share, a 45% premium to the closing price on Friday. Comparatively, Biogen has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. The P/E ratio of Alexion Pharmaceuticals is 35.83, which means that it is trading at a more expensive … Based on AstraZeneca's reference average ADR price of $54.14, this implies total consideration to Alexion shareholders of $39bn or $175 per share. Based on AstraZeneca's reference average ADR price of $54.14, this implies total consideration to Alexion shareholders of $39bn or $175 per share. ALXN updated stock price target summary. Find real-time ALXN - Alexion Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. The biotech has five marketed products, including one from its recent buyout of Portola Pharmaceuticals. Price to Earnings Ratio vs. the Market.
Outward Ps4 Worth It, Zwangsversteigerungen Bad Camberg, Zwergen- Und Riesenaufgaben Arbeitsblätter, Satisfactory Doggo Chow, Feuerwehreinsatz Heute Abend, Alternatives To Amazon Affiliate Program, Mindfactory Geld Zurück, Haus Mieten Riedlingen,